MedPath

Base Therapeutics (Shanghai) Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:0
Completed:0

Trial Phases

2 Phases

Early Phase 1:5
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Early Phase 1
5 (71.4%)
Not Applicable
2 (28.6%)

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Not Applicable
Not yet recruiting
Conditions
Gastric Cancer (GC)
Colorectal Cancer
Interventions
First Posted Date
2025-09-10
Last Posted Date
2025-09-10
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
15
Registration Number
NCT07166263
Locations
🇨🇳

Nanjing Drum Tower Hospital, Affiliated to the Medical School of Nanjing University, Nanjing, Jiangsu, China

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Not Applicable
Not yet recruiting
Conditions
Refractory Systemic Lupus Erythematosus
First Posted Date
2025-07-24
Last Posted Date
2025-07-28
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT07083349

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1
Recruiting
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06541405
Locations
🇨🇳

Shanghai Children's Medical Center, Shanghai, Shanghai, China

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Early Phase 1
Recruiting
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2024-08-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
9
Registration Number
NCT06541444
Locations
🇨🇳

Shanghai Pudong Hospital, Shanghai, Shanghai, China

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Early Phase 1
Recruiting
Conditions
Osteosarcoma
Soft Tissue Sarcoma
Interventions
First Posted Date
2023-11-07
Last Posted Date
2023-11-07
Lead Sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Target Recruit Count
12
Registration Number
NCT06117878
Locations
🇨🇳

Shanghai General Hospital, Shanghai, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.